Calderatx
4 known investors
Find your way into Calderatx
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases. Its lead candidate is in a Phase 1 healthy volunteer trial.
Founders & leadership
PT
Praveen TipirneniChief Executive Officer
LW
Liangsu WangChief Scientific Officer
ZL
Zhong LiuChief Technology Officer
AP
Aaron PeltaChief Business Officer
CW
Colm WhiteChief Program Officer
Investors · 4
Frequently asked questions
- What does Calderatx do?
- Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases. Its lead candidate is in a Phase 1 healthy volunteer trial.
- Who are Calderatx's investors?
- Calderatx's investors include Atlas Venture, Janus Henderson Investors, LAV, venBio Partners.